DGAP-Adhoc: Mologen AG: Positive preliminary results on clinical trial with anti-cancer drug

MOLOGEN AG / Miscellaneous

18.05.2009 

Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Berlin, May 18, 2009 - Patients' responses to the newly designed
anti-cancer drug MGN1703 of MOLOGEN AG exceeded expectations in clinical
trial. Therefore the biopharmaceutical company decided to extent the
on-going phase 1 study for a further dose increase.

The preliminary safety results show a favorable safety profile of MGN1703
in all patients treated with different doses of the cancer drug for up to 6
weeks. The evaluation of systemic and local tolerability of the treatment
exhibited very good results up to the dose of 30 mg.

A stable disease after completion of 6 weeks treatment was observed in over
40 per cent of the patients. Until now, four of the responding patients
were treated for further 6 weeks with the cancer drug. After completion of
the extension therapy, an ongoing stable disease was still observed in two
of these patients. The efficacy concept has been further confirmed by
investigations of the relationship between the administered dose and the
drug distribution in the body (pharmacokinetics) conducted within the scope
of this clinical trial.

Based on the favorable safety and pharmacokinetic results in all treatment
groups, Mologen AG has decided to extent the on-going study for a further
dose increase. Additional quantities of the cancer drug are currently being
manufactured. MOLOGEN expects to announce first results from this
additional dose group in the fourth quarter 2009. The company is currently
intensively engaged in preparing additional clinical trials investigating
the efficacy of MGN1703. A clinical trial phase 2 with colorectal cancer
patients is scheduled to start this year.




Contact: Jörg Petrass
Email: investor@mologen.com
Telephone: +49-30-84 17 88-13
Fax: +49-30-84 17 88-50

Kirchhoff Consult AG
Dr Kay Baden
Email: baden@kirchhoff.de
Telephone: +49-40-60 91 86 39



DGAP 18.05.2009 
---------------------------------------------------------------------------
 
Language:     English
Issuer:       MOLOGEN AG
              Fabeckstraße 30
              14195 Berlin
              Deutschland
Phone:        030 / 841788-0
Fax:          030 / 841788-50
E-mail:       info@mologen.com
Internet:     www.mologen.com
ISIN:         DE0006637200
WKN:          663720
Listed:       Regulierter Markt in Frankfurt; Freiverkehr in Berlin,
              München, Hamburg, Düsseldorf, Stuttgart
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------